CareDx Q2 Revenue Surges 52% to $132M, Swings to $111M Profit on Lab Products Sale
CDNA has more than doubled off its 52-week low of $11.259 on elevated volume (1.9× avg).
Summary
CareDx reported Q2 revenue of $131.9M (+52% YoY) and net income of $110.6M, driven by a $113M gain on the sale of its lab products business. Cash stands at $373.6M after the divestiture and the Naveris acquisition closed July 1. A final Medicare LCD affirms transplant test coverage.
Key Events · Earnings and Guidance · CDNA
-
Revenue Surges 52% to $131.9M
Testing services revenue grew 61% to $99.9M on 17% volume growth and $18M in prior-period collections. Total revenue reached $131.9M, up from $86.7M a year ago.
-
Swings to $110.6M Net Profit
Net income was $110.6M vs. a loss of $8.6M in Q2 2025, driven by a $113.0M gain on the sale of the lab products business. Excluding the gain, the core business also improved significantly.
-
Lab Products Sale Closes, Cash Surges to $373.6M
The $170M base-price sale of the lab products business closed June 30, generating $171.7M in proceeds and a $113M gain. Cash and equivalents ended the quarter at $373.6M, up from $65.4M at year-end.
-
Naveris Acquisition Completed July 1
CareDx acquired Naveris for $161.8M in cash plus up to $100M in revenue-based milestones, adding NavDx, a blood-based test for HPV-mediated cancers, to its oncology portfolio.
Analysis · CDNA · Industrial Applications And Services
A transformative quarter reshaped CareDx's trajectory. Revenue jumped 52% to $131.9 million, fueled by a 17% increase in testing volumes and $18 million from prior-period collections. The bottom line swung dramatically from a loss of $8.6 million a year ago to a net profit of $110.6 million, largely thanks to a $113 million gain on the sale of the lab products business. Following the $171.7 million divestiture and the July 1 close of the Naveris acquisition for $161.8 million, the balance sheet now holds $373.6 million in cash. A final Medicare LCD published July 16 affirms coverage for its transplant tests, removing a key overhang. Against this backdrop, the board authorized a new $100 million buyback. The combination of accelerating organic growth, a clean balance sheet, and regulatory clarity marks a turning point for the company.
At the time of this filing, CDNA was trading at $41.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $11.26 to $40.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.